Search for a trial | Research with human participants

1 results

An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-517429-24-00 check the CTIS register for the current data. Objectives:Primary:- Assess safety and tolerability of PDC*lung01 vaccinations administered at two dose levels as single agent or during…